

Mary L Disis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1270373/mary-l-disis-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

6,578
citations

35
h-index

81
g-index

105
ext. papers

8,826
ext. citations

8.3
avg, IF

6.05
L-index

#	Paper	IF	Citations
96	COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of Type I tumor infiltrating lymphocytes.. <i>Cancer Prevention Research</i> , 2022 ,	3.2	2
95	Breast cancer vaccines for treatment and prevention. <i>Breast Cancer Research and Treatment</i> , 2021 , 1	4.4	1
94	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021 , 26, 71-82	3	0
93	JAMA Oncology-The Year in Review, 2020. <i>JAMA Oncology</i> , 2021 , 7, 683-684	13.4	
92	Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021 , 12, 669474	8.4	16
91	Equity and the JAMA Network. <i>JAMA Health Forum</i> , 2021 , 2, e211638	2	1
90	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , 2021 , 27, 5472-5481	12.9	0
89	Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention. <i>Frontiers in Immunology</i> , 2021 , 12, 729809	8.4	5
88	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses. <i>Clinical Cancer Research</i> , 2021 , 27, 6405-6412	12.9	0
87	Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression models. <i>Laboratory Investigation</i> , 2021 ,	5.9	2
86	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.. <i>Journal of Cancer Prevention</i> , 2021 , 26, 309-317	3	
85	Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1102-1109	6.1	4
84	Oncology and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1141-1142	27.4	12
83	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , 2019 , 5, 393-401	13.4	178
82	The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice. <i>Cancer Prevention Research</i> , 2019 , 12, 507-516	3.2	4
81	JAMA Oncology-The Year in Review, 2018. <i>JAMA Oncology</i> , 2019 , 5, 609-610	13.4	
80	Current Landscape of Immunotherapy in Breast Cancer: A Review. <i>JAMA Oncology</i> , 2019 , 5, 1205-1214	13.4	143

79	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
78	TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells. <i>Journal of Leukocyte Biology</i> , 2018 , 103, 157-164	6.5	13
77	Immunologic Monitoring in Immuno-Oncology 2018 , 228-251		
76	Immunotherapy in breast cancer: An introduction. <i>Breast</i> , 2018 , 37, 196-199	3.6	30
75	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018 , 11, 735-778	3.2	19
74	Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 969-973	13.4	54
73	Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2017 , 144, 480-485	4.9	10
72	Gene expression markers of Tumor Infiltrating Leukocytes 2017 , 5, 18		308
71	Precancer Atlas to Drive Precision Prevention Trials. <i>Cancer Research</i> , 2017 , 77, 1510-1541	10.1	81
70	Immunization against HIF-1 α inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 3396-3404	12.9	21
69	Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer. <i>Seminars in Immunopathology</i> , 2017 , 39, 245-253	12	9
68	Scholarly productivity and professional advancement of junior researchers receiving KL2, K23, or K08 awards at a large public research institution. <i>Journal of Clinical and Translational Science</i> , 2017 , 1, 140-143	0.4	3
67	Movie Review of The Immortal Life of Henrietta Lacks. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 2410-2412	27.4	3
66	Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. <i>Oncotarget</i> , 2017 , 8, 10785-10808	3.3	10
65	Leveraging premalignant biology for immune-based cancer prevention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 10750-8	11.5	44
64	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016 , 8, 334ps9	17.5	115
63	Clinical significance of tumor-infiltrating lymphocytes in breast cancer 2016 , 4, 59		279
62	Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer. <i>Molecular Carcinogenesis</i> , 2016 , 55, 1517-1525	5	14

61	Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. <i>JAMA Oncology</i> , 2016 , 2, 1354-1360	13.4	271
60	Thank You JAMA Oncology Authors, Peer Reviewers, and Readers. <i>JAMA Oncology</i> , 2016 , 2, 435	13.4	
59	The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNF/IL17 Dependent. <i>Clinical Cancer Research</i> , 2016 , 22, 2207-16	12.9	15
58	Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. <i>PLoS ONE</i> , 2016 , 11, e0148764	3.7	40
57	Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo 2016 , 4, 27		19
56	An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. <i>Cancer Research</i> , 2015 , 75, 3246-54	10.1	29
55	Current methods of epitope identification for cancer vaccine design. <i>Vaccine</i> , 2015 , 33, 7408-7414	4.1	16
54	The Lasker Awards--Recognizing and Highlighting Oncology Research. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1123-4	27.4	
53	Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer 2015 , 3, 16		16
52	Triple-negative breast cancer: immune modulation as the new treatment paradigm. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e25-30	7.1	58
51	The antigenic repertoire of premalignant and high-risk lesions. <i>Cancer Prevention Research</i> , 2015 , 8, 266-70	3.0	12
50	Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5509-5509	2.2	68
49	Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. <i>Cancer Research</i> , 2014 , 74, 2710-8	10.1	29
48	HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 101-9	7.4	28
47	Mechanism of action of immunotherapy. <i>Seminars in Oncology</i> , 2014 , 41 Suppl 5, S3-13	5.5	89
46	Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. <i>Cancer Immunology Research</i> , 2014 , 2, 1071-9	12.5	90
45	Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer. <i>Journal of Translational Medicine</i> , 2014 , 12, 121	8.5	19
44	Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 501-10	4.4	9

43	Th1 epitope selection for clinically effective cancer vaccines. <i>Oncol Immunology</i> , 2014 , 3, e954971	7.2	7
42	JAMA Oncology® New Member of The JAMA Network Family of Journals. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1743	27.4	
41	Evaluation of cancer immunity in mice. <i>Cold Spring Harbor Protocols</i> , 2014 , 2014, 231-4	1.2	2
40	Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation. <i>Innate Immunity</i> , 2014 , 20, 857-66	2.7	12
39	T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 657-65	4.4	11
38	Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. <i>Immunobiology</i> , 2013 , 218, 1468-76	3.4	28
37	The invisible arm of immunity in common cancer chemoprevention agents. <i>Cancer Prevention Research</i> , 2013 , 6, 764-73	3.2	31
36	A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. <i>Cancer Prevention Research</i> , 2013 , 6, 1273-82	3.2	52
35	Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions. <i>Cancer Prevention Research</i> , 2013 , 6, 666-74	3.2	20
34	Can immunity to breast cancer eliminate residual micrometastases?. <i>Clinical Cancer Research</i> , 2013 , 19, 6398-403	12.9	16
33	Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. <i>Clinical Cancer Research</i> , 2012 , 18, 3122-31	12.9	37
32	Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 433-42	7.4	103
31	Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. <i>Clinical Cancer Research</i> , 2011 , 17, 67-76	12.9	101
30	Progress in the development of a therapeutic vaccine for breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010 , 2, 25-36	3.9	5
29	The road we must take: multidisciplinary team science. <i>Science Translational Medicine</i> , 2010 , 2, 22cm9	17.5	100
28	The ultimate in cancer chemoprevention: cancer vaccines. <i>Cancer Prevention Research</i> , 2010 , 3, 406-9	3.2	7
27	Immune regulation of cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4531-8	2.2	318
26	Wouldn't we all like to be a little more LEAN?. <i>Clinical and Translational Science</i> , 2010 , 3, 207-9	4.9	1

25	Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment. <i>Clinical Cancer Research</i> , 2009 , 15, 6476-8	12.9	16
24	Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4685-92	2.2	241
23	Use of tumour-responsive T cells as cancer treatment. <i>Lancet, The</i> , 2009 , 373, 673-83	40	127
22	Immunomodulation of breast cancer via tumor antigen specific Th1. <i>Cancer Research and Treatment</i> , 2009 , 41, 117-21	5.2	17
21	Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. <i>Cancer Research</i> , 2008 , 68, 8400-9	10.1	46
20	Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 449-54	6.1	42
19	Translational Oncology: Transforming Cancer Care. <i>Journal of Clinical Oncology</i> , 2007 , 25, 750-750	2.2	
18	Maximizing the retention of antigen specific lymphocyte function after cryopreservation. <i>Journal of Immunological Methods</i> , 2006 , 308, 13-8	2.5	120
17	Clinical use of subcutaneous G-CSF or GM-CSF in malignancy. <i>Oncology</i> , 2005 , 19, 5-9	1.8	7
16	Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. <i>Journal of Clinical Immunology</i> , 2004 , 24, 571-8	5.7	93
15	Monitoring immune responses in cancer patients receiving tumor vaccines. <i>International Reviews of Immunology</i> , 2003 , 22, 283-319	4.6	25
14	Future directions in the management of ovarian cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003 , 17, 1075-85	3.1	5
13	Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. <i>Immunobiology</i> , 2003 , 207, 179-86	3.4	24
12	Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. <i>Molecular Cancer Therapeutics</i> , 2003 , 2, 995-1002	6.1	10
11	Immunologic targets for breast cancer. <i>Breast Disease</i> , 2002 , 15, 83-90	1.6	5
10	Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. <i>Blood</i> , 2002 , 99, 2845-50	2.2	75
9	Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. <i>Clinical Cancer Research</i> , 2002 , 8, 1014-8	12.9	189
8	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. <i>Prostate</i> , 2001 , 47, 222-9	4.2	50

7	Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. <i>Journal of Clinical Investigation</i> , 2001 , 107, 477-84	15.9	302
6	Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. <i>Blood</i> , 2000 , 96, 1480-1489	5	5
5	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999 , 93, 2653-2659	2.2	35
4	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1999 , 93, 2653-2659	2.2	4
3	Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. <i>Advances in Experimental Medicine and Biology</i> , 1998 , 451, 511-8	3.6	15
2	Immunity to oncogenic proteins. <i>Immunological Reviews</i> , 1995 , 145, 33-59	11.3	153
1	Immunity to the HER-2/neu oncogenic protein. <i>Novartis Foundation Symposium</i> , 1994 , 187, 198-207; discussion 207-11		7